IP: Dr. Antonio Fernández Nebro
Líneas de Investigación
Las Líneas de investigación del Hospital Regional Universitario de Málaga son las siguientes:
- Epidemiología y patogenia de las enfermedades autoinmunes (Artritis Reumatoide, Espondiloartropatías, Lupus Eritematoso Sistémico y Esclerosis sistémica). Se analiza incidencia, espectro clínico y curso evolutivo de estas enfermedades.
- Riesgo cardiovascular y comorbilidades asociadas en enfermedades autoinmunes (Artritis Reumatoide, Artritis Idiopática juvenil, Espondiloartropatías y Lupus Eritematoso Sistémico). Estudiar todos aquellos marcadores asociados a la inflamación y la implicación de la inflamación en el desarrollo de eventos cardiovasculares y mortalidad precoz en pacientes con enfermedades inflamatorias reumatológicas crónicas.
- Estrategia terapéutica con agentes biológicos en pacientes con enfermedades autoinmunes (Artritis Reumatoide, Espondiloartropatías y Artritis psoriasica). Se estudia los efectos de los fármacos sobre la actividad inflamatoria y enfermedad cardiovascular. La optimización de dosis y predictores de respuesta a dichos fármacos.
Miembros del equipo
- Inmaculada Ureña Garnica
- Maria Victoria Irigoyen Oyarzabal
- Sara Manrique Arija
- Natalia Mena Vazquez
- María del Carmen Ordoñez Cañizares
- Carmen Maria Romero Barco
Selección de Publicaciones recientes
Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology.
María Pego-Reigosa J; Lois-Iglesias A; Rúa-Figueroa Í; Galindo M; Calvo-Alén J; de Uña-Álvarez J; Balboa-Barreiro V; Ibáñez Ruan J; Olivé A; Rodríguez-Gómez M; Fernández Nebro A; Andrés M; Erausquin C; Tomero E; Horcada Rubio L; Uriarte Isacelaya E; Freire M; Montilla C; Sánchez-Atrio AI; Santos-Soler G; Zea A; Díez E; Narváez J; Blanco-Alonso R; Silva-Fernández L; Esther Ruiz-Lucea M; Fernández-Castro M; Ángel Hernández-Beriain J; Gantes-Mora M; Hernández-Cruz B; Pérez-Venegas J; Pecondón-Español Á; Marras Fernández-Cid C; Ibáñez-Barcelo M; Bonilla G; Torrente-Segarra V; Castellví I; José Alegre J; Calvet J; Luis Marenco de la Fuente J; Raya E; Ramón Vázquez-Rodríguez T; Quevedo-Vila V; Muñoz-Fernández S; Otón T; Rahman A; Javier López-Longo F. Lupus Registry. Rheumatology (Oxford) 2016 Jul;55(7):1243-50. doi: 10.1093/rheumatology/kew049. Epub 2016 Mar 27. PMID: 27018057. FI: 4.524 (Q1).
A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis.
Julià A; González I; Fernández-Nebro A; Blanco F; Rodriguez L; González A; Cañete JD; Maymó J; Alperi-López M; Olivé A; Corominas H; Martínez-Taboada V; Erra A; Sánchez-Fernández S; Alonso A; Lopez-Lasanta M; Tortosa R; Codó L; Gelpi JL; García-Montero AC; Bertranpetit J; Absher D; Bridges SL; Myers RM; Tornero J; Marsal S. Rheumatology (Oxford) 2016 Jun;55(6):1106-11. doi: 10.1093/rheumatology/kew035. Epub 2016 Mar 15. PMID: 26983453. FI: 4.524 (Q1).
Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review.
Rodríguez-García V; Ioannou Y; Fernández-Nebro A; Isenberg DA; Giles IP. Rheumatology (Oxford) 2015 Nov;54(11):2042-50. doi: 10.1093/rheumatology/kev226. Epub 2015 Jul 7. Review. PMID: 26152548. FI: 4.524 (Q1).
A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk.Annals of the rheumatic diseases.
Julià A; Pinto JA; Gratacós J; Queiró R; Ferrándiz C; Fonseca E; Montilla C; Torre-Alonso JC; Puig L; Pérez Venegas JJ; Fernández Nebro A; Fernández E; Muñoz-Fernández S; Daudén E; González C; Roig D; Sánchez Carazo JL; Zarco P; Erra A; López Estebaranz JL; Rodríguez J; Ramírez DM; de la Cueva P; Vanaclocha F;Herrera E; Castañeda S; Rubio E; Salvador G; Díaz-Torné C; Blanco R; Willisch Domínguez A; Mosquera JA; Vela P; Tornero J; Sánchez-Fernández S; Corominas H; Ramírez J; López-Lasanta M; Tortosa R; Palau N; Alonso A; García-Montero AC; Gelpí JL; Codó L; Day K; Absher D; Myers RM; Cañete JD; Marsal S. Ann Rheum Dis. 2015 Oct;74(10):1875-81. doi: 10.1136/annrheumdis-2014-207190. Epub 2015 May 19. PMID: 25990289. FI: 12.384 (D1).
Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.
Fernández-Nebro A; Rúa-Figueroa Í; López-Longo FJ; Galindo-Izquierdo M; Calvo-Alén J; Olivé-Marqués A; Ordóñez-Cañizares C; Martín-Martínez MA; Blanco R; Melero-González R; Ibáñez-Rúan J; Bernal-Vidal JA; Tomero-Muriel E; Uriarte-Isacelaya E; Horcada-Rubio L; Freire-González M; Narváez J; Boteanu AL; Santos-Soler G; Andreu JL; Pego-Reigosa JM; EAS-SER (Systemic Diseases Study Group of Spanish Society of Rheumatology). Medicine (Baltimore) 2015 Jul;94(29):e1183. doi: 10.1097/MD.0000000000001183. PMID: 26200625. FI: 2.133 (Q2).
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
Cervera R; Serrano R; Pons-Estel GJ; Ceberio-Hualde L; Shoenfeld Y; de Ramón E; Buonaiuto V; Jacobsen S; Zeher MM; Tarr T; Tincani A; Taglietti M; Theodossiades G; Nomikou E; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Fernández-Nebro A; Haro M; Amoura Z; Miyara M; Tektonidou M; Espinosa G; Bertolaccini ML; Khamashta MA; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Ann Rheum Dis. 2015 Jun;74(6):1011-8. doi: 10.1136/annrheumdis-2013-204838. Epub 2014 Jan 24. PMID: 24464962. FI: 12.384 (D1).
Replication of PTPRC as genetic.biomarker of response to TNF inhibitors in patients with rheumatoid arthritis.
Ferreiro-Iglesias A; Montes A; Perez-Pampin E; Cañete JD; Raya E; Magro-Checa C; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Joven B; Carreira P; Balsa A; Pascual-Salcedo D; Blanco FJ; Moreno-Ramos MJ; Fernández-Nebro A; Ordóñez MC; Alegre-Sancho JJ; Narváez J; Navarro-Sarabia F; Moreira V; Valor L; García-Portales R; Marquez A; Martin J; Gómez-Reino JJ; Gonzalez A. Pharmacogenomics J. 2016 Apr;16(2):137-40. doi: 10.1038/tpj.2015.29. Epub 2015 Apr 21. PMID: 25896535. FI: 4.229 (Q1).
A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis.
Julià A; Fernandez-Nebro A; Blanco F; Ortiz A; Cañete JD; Maymó J; Alperi-López M; Fernández-Gutierrez B; Olivè A; Corominas H; Erra A; Acosta-Colman I; Alonso A; López-Lasanta M; Tortosa R; Tornero J; Marsal S. Pharmacogenomics J. 2016 Apr;16(2):147-50. doi: 10.1038/tpj.2015.31. Epub 2015 Apr 21. PMID: 25896534. FI: 4.229 (Q1).
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.
Montes A; Perez-Pampin E; Navarro-Sarabia F; Moreira V; de la Serna AR; Magallares B; Vasilopoulos Y; Sarafidou T; Fernández-Nebro A; Ordóñez Mdel C; Narváez J; Cañete JD; Marquez A; Pascual-Salcedo D; Joven B; Carreira P; Moreno-Ramos MJ; Caliz R; Ferrer MA; Garcia-Portales R; Blanco FJ; Magro C; Raya E; Valor L; Alegre-Sancho JJ; Balsa A; Martin J; Plant D; Isaacs J; Morgan AW; Barton A; Wilson AG; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS); Gómez-Reino JJ; Gonzalez A. Arthritis Res Ther. 2015 Mar 18;17:63. doi: 10.1186/s13075-015-0571-z. PMID: 25885039. FI: 3.979 (Q1).
Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis.
Avila-Pedretti G; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Alperiz M; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Aterido A; López Lasanta M; Tortosa R; Julià A; Marsal S. PLoS One. 2015 Apr 7;10(4):e0122088. doi: 10.1371/journal.pone.0122088. eCollection 2015. PMID: 25848939. FI: 3.057 (Q1).
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review.
Cobo-Ibáñez T; Loza-Santamaría E; Pego-Reigosa JM; Marqués AO; Rúa-Figueroa I; Fernández-Nebro A; Cáliz RC; López Longo FJ; Muñoz-Fernández S. Semin Arthritis Rheum. 2014 Oct;44(2):175-85. doi: 10.1016/j.semarthrit.2014.04.002. Epub 2014 Apr 13. Review. PMID: 24830791. FI: 3.925 (Q1).
The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB).
Fernández-Nebro A; Marenco J; López-Longo F; Galindo M; Hernández-Cruz B; Narváez J; Rúa-Figueroa II; Raya-Alvarez E; Zea A; Freire M; Sánchez-Atrio A; García-Vicuña R; Pego-Reigosa J; Manrique-Arija S;Nieves-Martín L; Carreño L; on behalf of LESIMAB GROUP. Lupus. 2014 Sep;23(10):1014-22. doi: 10.1177/0961203314534909. Epub 2014 May 15. PMID: 24833667. FI: 2.197 (Q3).
Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.
Montes A; Perez-Pampin E; Narváez J; Cañete JD; Navarro-Sarabia F; Moreira V; Fernández-Nebro A; Del Carmen Ordóñez M; de la Serna AR; Magallares B; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Joven B; Carreira P; Gómez-Reino JJ; Gonzalez A. Pharmacogenet Genomics. 2014 May; 24(5):238-45. doi: 10.1097/FPC.0000000000000042. PMID: 24667440. FI: 3.481 (Q1).
A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci.
Martin JE; Assassi S; Diaz-Gallo LM; Broen JC; Simeon CP; Castellvi I; Vicente-Rabaneda E; Fonollosa V; Ortego-Centeno N; González-Gay MA; Espinosa G; Carreira P; Spanish Scleroderma Group; SLEGEN consortium; U.S. Scleroderma GWAS group; BIOLUPUS; Camps M; Sabio JM; D’alfonso S; Vonk MC; Voskuyl AE; Schuerwegh AJ; Kreuter A; Witte T; Riemekasten G; Hunzelmann N; Airo P; Beretta L; Scorza R; Lunardi C; Van Laar J; Chee MM; Worthington J; Herrick A; Denton C; Fonseca C; Tan FK; Arnett F; Zhou X; Reveille JD; Gorlova O; Koeleman BP; Radstake TR; Vyse T; Mayes MD; Alarcón-Riquelme ME; Martin J. Hum Mol Genet 2013 Oct 1; 22(19): 4021-9. PMID: 23740937. FI: 6.677 (D1).
GWAS replication study c onfirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.
Acosta-Colman I; Palau N; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J;Ballina J; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Canela-Xandri O; Alonso A; López Lasanta M;Tortosa R; Julià A; Marsal S. Pharmacogenomics. 2013 May;14(7):727-34. doi: 10.2217/pgs.13.60. PMID: 236510214. FI: 3.425 (Q1).
New insight on the Xq28 association with systemic sclerosis.
Carmona FD; Cénit MC; Diaz-Gallo LM; Broen JC; Simeón CP; Carreira PE; Callejas-Rubio JL; Fonollosa V; López-Longo FJ; González-Gay MA; Hunzelmann N; Riemekasten G; Witte T; Kreuter A; Distler JH; Madhok R; Shiels P; van Laar JM; Schuerwegh AJ; Vonk MC; Voskuyl AE; Fonseca C; Denton CP; Herrick A; Worthington J; Arnett FC; Tan FK; Assassi S; Radstake TR; Mayes MD; Martín J; Spanish Scleroderma Group. Ann Rheum Dis. 2013 Dec; 72(12): 2032-8. PMID: 23444193. FI: 9.27 (D1).
Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis.
Descalzo MÁ; Garcia VV; González-Alvaro I; Carbonell J; Balsa A; Sanmartí R; Lisbona P; Hernandez-Barrera V; Jiménez-Garcia R; Carmona L; SERAP Study Group. Rheumatology (Oxford). 2013 Feb; 52(2):331-6. doi: 10.1093/rheumatology/kes245. Epub 2012 Sep 29. PMID: 23024115. FI: 4.435 (Q1).
Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes.
Julià A; Tortosa R; Hernanz JM; Cañete JD; Fonseca E; Ferrándiz C; Unamuno P; Puig L; Fernández-Sueiro JL; Sanmartí R; Rodríguez J; Gratacós J; Dauden E; Sánchez-Carazo JL; López-Estebaranz JL; Moreno-Ramírez D; Queiró R; Montilla C; Torre-Alonso JC; Pérez-Venegas JJ; Vanaclocha F; Herrera E; Muñoz-Fernández S; González C; Roig D; Erra A; Acosta I; Fernández-Nebro A; Zarco P; Alonso A; López-Lasanta M; García-Montero A; Gelpí JL; Absher D; Marsal S. Hum Mol Genet. 2012 Oct 15;21(20):4549-57. Epub 2012 Jul 19. PMID: 22814393. FI: 7.692. (D1).
Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis.
Teruel M; Simeon CP; Broen J; Vonk MC; Carreira P; Camps MT; García-Portales R; Delgado-Frías E; Gallego M; Espinosa G; Spanish Scleroderma Group; Beretta L; Airó P; Lunardi C; Riemekasten G; Witte T; Krieg T; Kreuter A; Distler JH; Hunzelmann N; Koeleman BP; Voskuyl AE; Schuerwegh AJ; González-Gay MA; Radstake TR; Martin J. Arthritis Res Ther. 14, pp. R154. PMID: 22731751. FI: 4.302 (Q1).
Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up.
Martin JE; Broen JC; Carmona FD; Teruel M; Simeon CP; Vonk MC; van ‘t Slot R; Rodriguez-Rodriguez L; Vicente E; Fonollosa V; Ortego-Centeno N; González-Gay MA; García-Hernández FJ; de la Peña PG; Carreira P; Spanish Scleroderma Group; Voskuyl AE; Schuerwegh AJ; van Riel PL; Kreuter A; Witte T; Riemekasten G; Airo P; Scorza R; Lunardi C; Hunzelmann N; Distler JH; Beretta L; van Laar J; Chee MM; Worthington J; Herrick A; Denton C; Tan FK; Arnett FC; Assassi S; Fonseca C; Mayes MD; Radstake TR; Koeleman BP; Martin J. Hum Mol Genet. 2012 Jun 15;21(12):2825-35. doi: 10.1093/hmg/dds099. Epub 2012 Mar 9. PMID: 22407130. FI: 7.692 (D1).